Presentation is loading. Please wait.

Presentation is loading. Please wait.

Journal of Thoracic Oncology

Published byBlanche Hubbard Modified over 5 years ago

Similar presentations

Presentation on theme: "Journal of Thoracic Oncology"— Presentation transcript:

1 Journal of Thoracic Oncology
Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes  Wade T. Iams, MD, Eileen Shiuan, BS, Catherine B. Meador, MD, PhD, Marc Roth, MD, Jennifer Bordeaux, PhD, Christine Vaupel, PhD, Kelli L. Boyd, DVM, PhD, IlaSri B. Summitt, PhD, Lucy L. Wang, PhD, Joseph T. Schneider, MS, Jeremy L. Warner, MD, MS, Zhiguo Zhao, MS, Christine M. Lovly, MD, PhD  Journal of Thoracic Oncology  DOI: /j.jtho Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Progression-free survival (PFS) and overall survival (OS) according to the presence and type of paraneoplastic syndrome (PNS) in patients with SCLC. Kaplan-Meier estimates of (A) OS and (B) PFS in patients with SCLC according to the absence or presence of a PNS. Kaplan-Meier estimates of (C) OS and (D) PFS limited to only patients who received systemic therapy for SCLC. Journal of Thoracic Oncology DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Overall comparison of CD3, CD4, CD8, and programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) interaction scores. Tumors from patients with SCLC with neurologic paraneoplastic syndromes (PNS) had significantly increased PD-1/PD-L1 interaction scores (A) compared to tumors from patients with SCLC with endocrinologic PNS and tumors from patients with SCLC and no paraneoplastic syndrome (control). Tumors from patients with SCLC with neurologic PNS had a trend towards increased CD4 (B) and CD8 (C) infiltrates compared to tumors from patients with SCLC with endocrinologic PNS and tumors from patients with SCLC and no PNS (control). Tumors from patients with SCLC with neurologic PNS had significantly increased CD3 (D) infiltrates compared to tumors from patients with SCLC with endocrinologic PNS and tumors from patients with SCLC and no PNS (control). Journal of Thoracic Oncology DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Immunologic correlates by automated quantitative analysis with accompanying computed tomography (CT). (A) ×4 and ×20, 40,6-diamidino-2-phenylindole (DAPI) in blue, transcription termination factor 1 (TTF1) in green, programmed death 1 (PD-1) in yellow, and programmed death ligand 1 (PD-L1) in red. (B) ×20, DAPI in blue, CD3 in yellow, CD4 in red, and CD8 in green (first image with CD3 present, second image with CD3 removed). (C) CT scan shows the primary tumor at diagnosis (left) followed by progression of disease (right, red arrow indicates primary tumor in both panels). Journal of Thoracic Oncology DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Journal of Thoracic Oncology"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma  Maria I. Toki, MD,

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma  Maria I. Toki, MD,
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse  Karinna.

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse  Karinna.
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.
Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization 

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization 
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung  Zhigang.

Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung  Zhigang.
Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer  Patrick Wald,

Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer  Patrick Wald,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment  Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment  Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,
Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis 

Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis 

Similar presentations

Ads by Google